Key Segments:
By Test Type
-
Preliminary Tests
-
PSA Tests
-
Free PSA Test
-
Total PSA Test
-
Other Preliminary Tests
-
-
Confirmatory Tests
-
Pca3 Test
-
Trans-Rectal Ultrasound
-
Biopsy Test
-
By Type
-
Adenocarcinoma
-
Interstitial Cell Carcinoma
-
Other
By End User
-
Hospitals
-
Outpatient Facilities
-
Home Care
-
Research & Manufacturing
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Prostate Cancer Diagnostics Market in 2025.
The Confirmatory Tests segment is expected to register the fastest CAGR through 2035.
The Rising Prevalence of Prostate Cancer and the Growing Geriatric Population Accelerating the Prostate Cancer Diagnostics Market.
The Prostate Cancer Diagnostics Market was valued at USD 9.72 billion in 2025.
The Prostate Cancer Diagnostics Market is expected to grow at a CAGR of 6.50% from 2026 to 2035.